160 Health International Limited, a leading digital healthcare service provider in China, began trading on the main board of the Hong Kong Stock Exchange on Sept. 17, bringing the total number of listed companies in Nanshan District to 218.

The company offered 33.6455 million shares globally at HK$11.89 (US$1.52) per share, with its first-day closing price reaching HK$28.22, a surge of 137.34%. The offering raised HK$400 million, which will be used to expand medical resource coverage, strengthen research and development capabilities, enrich products and services, and explore value-added services, strategic partnerships, and acquisitions, as well as for working capital and general corporate purposes.

Founded in Nanshan in 2005, 160 Health has leveraged internet technology and innovative models to improve the operational efficiency of healthcare institutions, assist medical staff in patient management, and meet the diverse needs of individual users during medical treatment. After 20 years of development, the company has built a healthcare service platform that deeply connects hospitals, clinics, doctors, and users.

As of the end of March 2025, the company's business covered more than 260 cities nationwide, connecting over 44,600 healthcare institutions and collaborating with more than 900,000 medical professionals.

Nanshan, as the core cluster area for Shenzhen's biomedical industry, has gradually formed three major advantageous fields: innovative drugs, high-end medical devices, and digital healthcare. The district is home to many high-quality enterprises such as Mindray, CMS, and Chipscreen Biosciences, establishing a complete chain from basic research to industrialization and making breakthroughs in innovative drugs for tumors, autoimmune diseases, and central nervous system disorders.

Since the beginning of this year, 15 additional companies in Nanshan have applied for overseas listings.